Human Stem Cells Institute OJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.

HSCI owns the largest family cord blood stem cell bank in Russia – Gemabank, as well as the reproductive cell and tissue bank Reprobank (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene-therapy drug for treating Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant project to create its own Russia-wide network of Genetico medical centers & testing lab to provide a range of genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders (incl. PGD and NIPT among others).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

Ask a question

What is SPRS therapy?

The SPRS therapy is based on skin injections of patient's own skin fibroblasts that are functionally active and have been obtained from a small skin sample at the specialized laboratory. Fibroblasts are expanded in cell culture until they reach an amount required for the therapy. During cultivation only young and highly active cells are selected while old and inactive cells are removed. Then the cells are injected into the problem skin regions under clinical conditions.

Since fibroblasts were obtained from patient's own skin, they easily survive in patient's skin and promote efficient correction of age-related skin changes by active producing all the necessary skin components, i.e., collagen, elastin, hyaluronic acid, etc. The studies have been shown that in one year after the end of procedure, the skin density increases by 64%. This is accompanied by the increase of skin elasticity and firmness while the depth and amount of wrinkles is decreased.

SPRS therapy - the technology that allows one not only to remove small and average wrinkles but also to increase the thickness, tension, and elasticity of the skin. This procedure not only results in visual correction of the age-related skin changes, but also removes the cause of skin aging owing to enlargement of the skin fibroblasts population which decreases in number with age.

The SPRS therapy is based on application of autologous (i.e., patient's own) skin cells, fibroblasts. Fibroblasts are the main skin cells responsible for production of skin "youth" components: collagen, elastin, and hyaluronic acid. With age, the amount of fibroblasts in skin is decreased, as well as their biosynthetic activity and collagen content. Thus, American scientists have shown that in the skin of old people, the number of fibroblasts and their biosynthetic activity is decreased by 40% and 75%, respectively, as compared with the skin of young people.

The visual appearance of these processes is wrinkle formation and the decrease of skin thickness and elasticity. Briefly, the SPRS therapy can be described as follows: patient's skin sample of 4 mm in size is used to obtain a cell suspension containing cultivated autologous fibroblasts at the specialized laboratory of the Human Stem Cell Institute. The course of the skin therapy consists of 2 procedures separated with a one-month interval. The obtained cell suspension (the SPRS preparation) is delivered to the cosmetological clinic immediately before each procedure.

The cells are injected according to the special procedure intracutaneously (into the papillary layer of the derma) by tunnel mode using special mesotherapeutic needles which allow one to evenly distribute (with the adequate cell density) new functionally active fibroblasts throughout the skin region that requires correction. This completely excludes patient's body immune response since only patient's own cells are used for the procedure.

The autologous fibroblasts injected into the skin efficiently correct the age-related skin changes since, being transplanted into the skin, they intensively produce collagen, elastin, and the other important skin "youth" components. As a result, the skin microstructure is restored and the skin density and elasticity is increased whereas the amount and depth of wrinkles is decreased. Thus, as opposed to Botox injections, the SPRS therapy is an absolutely safe cosmetological method having no side effects owing to application of patient's own cells which perfectly survive in patient's skin. This promotes the long-term clinical effect that is maintained for several years.